Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyNet Income - MinorityNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Teva Pharmaceutical Industries (TEVJF) Income towards Parent Company (2016 - 2025)

Teva Pharmaceutical Industries (TEVJF) has disclosed Income towards Parent Company for 10 consecutive years, with $466.0 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Income towards Parent Company rose 264.66% year-over-year to $466.0 million, compared with a TTM value of $466.0 million through Dec 2025, up 264.66%, and an annual FY2025 reading of $1.4 billion, up 171.12% over the prior year.
  • Income towards Parent Company was $466.0 million for Q4 2025 at Teva Pharmaceutical Industries, down from $642.0 million in the prior quarter.
  • Across five years, Income towards Parent Company topped out at $642.0 million in Q3 2025 and bottomed at -$2.1 billion in Q4 2022.
  • Average Income towards Parent Company over 5 years is -$685.9 million, with a median of -$702.0 million recorded in 2022.
  • The sharpest move saw Income towards Parent Company plummeted 111.53% in 2022, then soared 264.66% in 2025.
  • Year by year, Income towards Parent Company stood at -$1.1 billion in 2021, then crashed by 90.51% to -$2.1 billion in 2022, then skyrocketed by 91.17% to -$188.0 million in 2023, then crashed by 50.53% to -$283.0 million in 2024, then skyrocketed by 264.66% to $466.0 million in 2025.
  • Business Quant data shows Income towards Parent Company for TEVJF at $466.0 million in Q4 2025, $642.0 million in Q3 2025, and $203.0 million in Q2 2025.